News Conference News ESC 2020 EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class Michael O'Riordan August 29, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Daily News US Mortality Rates for CVD Have Stalled as Racial Disparities Widen Yael L. Maxwell August 19, 2020
News Daily News HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds Michael O'Riordan August 13, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Features COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions Shelley Wood July 20, 2020
News Daily News Higher Risk of HF After ACS for Women Previously on Beta-blockers Michael O'Riordan July 16, 2020
News Daily News No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests Yael L. Maxwell May 21, 2020
News Daily News COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk Michael O'Riordan May 05, 2020
News Features Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance Shelley Wood April 29, 2020
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020
News Daily News Missed Opportunities: Many HF Patients Not Tested for CAD L.A. McKeown March 20, 2020
News Daily News COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say Todd Neale March 17, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Daily News Trials of New Cancer Drugs Failing to Address Potential CV Risks Todd Neale February 10, 2020
News Daily News Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis Caitlin E. Cox February 07, 2020
News Daily News Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk Caitlin E. Cox January 14, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2019 Shelley Wood December 31, 2019